Log in Free sign up

Corcept Therapeutics (CORT) News and press releases

News

From Benzinga Pro

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Biotech, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Stock Split, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Corcept Therapeutics Commences Late-Stage Ovarian Cancer Study

Biotech, Health Care, General

Corcept Therapeutics (NASDAQ: CORT) has initiated pivotal Phase 3 clinical trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial In Recurrent, Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated

Corcept Therapeutics To Start Phase 3 Trial Of Relacorilant Plus Nab-Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer

Biotech, News, FDA, General

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating

Corcept Therapeutics Q1 EPS $0.20 Misses $0.24 Estimate, Sales $93.70M Miss $98.88M Estimate

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.20 per share which missed the analyst consensus estimate of $0.24 by 16.67 percent. This is unchanged from the same period last year. The company

Earnings Scheduled For May 5, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.

Preview: Corcept Therapeutics's Earnings

Corcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Corcept Therapeutics will report an earnings per share (EPS) of $0.24.

Press releases

From Benzinga Pro

Bragar Eagel & Squire, P.C. Is Investigating Agrify, Carvana, Enochian, and Corcept and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, June 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agrify Corporation (NASDAQ:AGFY), Carvana Co.

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 29, 2022)

Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer

Health Care, Press Releases

MENLO PARK, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine,

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Corcept Therapeutics Incorporated

Wilmington, Delaware--(Newsfile Corp. - June 28, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Corcept Therapeutics Incorporated (NASDAQ:CORT) on behalf of

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 26, 2022)

Bragar Eagel & Squire, P.C. Is Investigating Unity, Carvana, Enochian, and Corcept and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Unity Software, Inc. (NYSE:U), Carvana Co.

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Corcept, and Clariant and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE:CVNA), Enochian Biosciences,

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 19, 2022)

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Novartis, and Corcept and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE:CVNA), Enochian Biosciences,

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 12, 2022)

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Enochian, Novartis, and Corcept and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE:CVNA), Enochian Biosciences,

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 5, 2022)

Bragar Eagel & Squire, P.C. Is Investigating Verrica, Gap, and Corcept and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verrica Pharmaceuticals, Inc. (NASDAQ:VRCA),

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their Options

Legal, Press Releases

NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Corcept Therapeutics Inc. ("Corcept" or the

Bragar Eagel & Squire, P.C. Is Investigating Medallion, Corcept, RBB, and Cassava and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Medallion Financial Corp. (NASDAQ:MFIN),

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their Options

Legal, Press Releases

NEW YORK, NY / ACCESSWIRE / May 29, 2022 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Corcept Therapeutics Inc. ("Corcept" or the

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 25, 2022)

Bragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Corcept, and RBB and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, May 22, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CareDx, Inc. (NASDAQ:CDNA), Medallion Financial

Corcept Investor Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 22, 2022)

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Corcept To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 18, 2022)